Sling Therapeutics, Inc.
A clinical-stage biotechnology company developing an oral drug candidate for thyroid eye disease.
$123MSeries C
LeadF
Forbion
Activity from announced rounds
Activity in this selectionsemcap-ai-730836bb
Forbion is an investment firm whose official portfolio and financing news identify CellCentric, Sling and Solstice.
Recorded funding activity
Sling develops an oral medicine for thyroid eye disease. Solstice advances an engineered cancer-immunotherapy antibody, while RQ Bio develops preventive antibodies for vulnerable patients facing influenza. These are separate clinical programs and company financings.
Sources
- Rounds participated in
- 7
- Confirmed lead rounds
- 1 5 roles undisclosed
- New companies
- 7 First participation on record · 0 follow-on
- Funding in participating rounds
- $968M 7 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
7 in this selectionSolstice Oncology
A clinical-stage immunotherapy company is advancing an engineered CTLA-4 antibody for earlier cancer treatment.
$225MSeries A
ParticipantRQ Bio
Develops antibody therapies to prevent seasonal influenza in high-risk and immunocompromised patients
$115MSeries A
Role not disclosedCellCentric
Develops inobrodib, a first-in-class oral p300/CBP inhibitor for relapsed or refractory multiple myeloma
$220MSeries D
Role not disclosedSlate Medicines
Advancing next-generation therapeutics for migraine and other headache disorders
$130MSeries A
Role not disclosedAltesa BioSciences
Clinical-stage developer of oral antiviral medicines for people with chronic lung disease.
$75MSeries B
Role not disclosedCorsera Health
Develops preventive RNAi medicines for cardiovascular disease prediction and prevention
$80MSeries A
Role not disclosed